Nasdaq · CIK 0001980845
ENGN enGene Holdings Inc.
Insider trading from SEC Form 4. Last filing 18 d ago. Close $1.73 on Oct 9, 2026, +20% from the 52-week low and -86% from the high.
Last 90 days
Net insider value
+$10k
more bought than sold
Buys
1
$10k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
18
with a Form 4 at this company
Price and insider trades, last year
ENGNOct 9, 2026 · close 1.73
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at enGene Holdings Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | William Grossman Interim Chief Medical Officer buy | $10k 5,102 shares | - | - | |
| 38Weak | Forbion Growth Opportunities Fund I Cooperatief U.A. owner buy | $5.0M 561,797 shares | +23% | - | |
| 38Weak | Forbion Growth Opportunities Fund I Cooperatief U.A. owner buy | $3.0M 470,633 shares | +24% | - |
Transactions
The last 33 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | William Grossman Interim Chief Medical Officer | POpen-market purchase Common Shares | +5,102 | $1.97 | $10k | 5,102 | 18 d ago |
| Jul 8, 2025 | Matthew Ross Boyd Chief Regulatory Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jul 14, 2025 |
| Jul 8, 2025 | Philip Astley-Sparke director | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jul 10, 2025 |
| Jul 8, 2025 | Jill Buck Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jul 10, 2025 |
| Jul 8, 2025 | William Grossman Interim Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jul 10, 2025 |
| Jul 8, 2025 | Michael Thomas Heffernan director | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jul 10, 2025 |
| Jun 16, 2025 | Gerald A Brunk director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 16, 2025 |
| Jun 16, 2025 | Jasper Bos director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 16, 2025 |
| Jun 16, 2025 | Richard M Glickman director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 16, 2025 |
| Jun 16, 2025 | Paul J Hastings director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 16, 2025 |
| Jun 16, 2025 | Wouter Joustra director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 16, 2025 |
| Jun 16, 2025 | Amy Pott Chief Global Comm. Ofc. | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jun 16, 2025 |
| Jun 16, 2025 | Lota S. Zoth director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 16, 2025 |
| Jan 29, 2025 | Lee Giguere Chief Legal Ofc. and Corp Secy | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jan 31, 2025 |
| Jan 29, 2025 | D. Ryan Daws Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Jan 31, 2025 |
| Jan 29, 2025 | Anthony Tzeyew Cheung Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jan 31, 2025 |
| Jan 29, 2025 | Ronald Harold Wilfred Cooper CEO & President | AGrant or award Stock Option (Right to Buy)derivative | +850,000 | $0.00 | $0 | 850,000 | Jan 31, 2025 |
| Oct 30, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +561,797 | $8.90 | $5.0M | 3,032,430 | Nov 1, 2024 |
| Oct 21, 2024 | Anthony Tzeyew Cheung Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Oct 22, 2024 |
| Oct 21, 2024 | Joan Connolly Chief Technology Officer | AGrant or award Stock Option (Right to Buy)derivative | +210,000 | $0.00 | $0 | 210,000 | Oct 22, 2024 |
| Dec 27, 2023 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +2,750 | $7.17 | $20k | 2,002,750 | Oct 18, 2024 |
| Dec 28, 2023 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +5,050 | $7.69 | $39k | 2,007,800 | Oct 18, 2024 |
| Dec 29, 2023 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +400 | $8.30 | $3,320 | 2,008,200 | Oct 18, 2024 |
| Dec 29, 2023 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +9,620 | $9.09 | $87k | 2,017,820 | Oct 18, 2024 |
| Sep 27, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +38,396 | $5.94 | $228k | 2,056,216 | Oct 18, 2024 |
| Sep 27, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +3,243 | $6.38 | $21k | 2,059,459 | Oct 18, 2024 |
| Sep 30, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +341,332 | $6.34 | $2.2M | 2,400,791 | Oct 18, 2024 |
| Oct 1, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +35,279 | $6.44 | $227k | 2,436,070 | Oct 18, 2024 |
| Oct 2, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +10,153 | $6.37 | $65k | 2,446,223 | Oct 18, 2024 |
| Oct 3, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +5,769 | $6.48 | $37k | 2,451,992 | Oct 18, 2024 |
| Oct 4, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +5,997 | $6.54 | $39k | 2,457,989 | Oct 18, 2024 |
| Oct 7, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +11,844 | $6.55 | $78k | 2,469,833 | Oct 18, 2024 |
| Oct 8, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | POpen-market purchase Common Shares | +800 | $6.60 | $5,278 | 2,470,633 | Oct 18, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Philip Astley-Sparkedirector
- Gerald A Brunkdirector
- Jasper Bosdirector
- Matthew Ross BoydChief Regulatory Officer
- Jill BuckChief Development Officer
- Anthony Tzeyew CheungChief Scientific Officer
- Joan ConnollyChief Technology Officer
- Ronald Harold Wilfred CooperCEO & President
- D. Ryan DawsChief Financial Officer
- Forbion Growth Opportunities Fund I Cooperatief U.A.owner
- Lee GiguereChief Legal Ofc. and Corp Secy
- Richard M Glickmandirector
- William GrossmanInterim Chief Medical Officer
- Paul J Hastingsceo, officer, director
- Michael Thomas Heffernandirector
- Wouter Joustradirector
- Amy PottChief Global Comm. Ofc.
- Lota S. Zothdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.